ArticleBMC infectious diseases2026
Trends of severe human metapneumovirus infections in India.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
85 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn December 2024 and early January 2025, China reported increased acute respiratory infections with increased detections of seasonal influenza, rhinovirus, RSV and hMPV during the Northern Hemisphere winter. We strengthened hMPV surveillance through the existing pan-India surveillance network for acute respiratory illness (ARI) and severe acute respiratory infection (SARI). METHODOLOGY: To rapidly generate nationwide situational data without overburdening laboratories already performing routine respiratory virus surveillance, each site was asked to test up to five eligible SARI samples per week for hMPV from January to April 2025. Eligible samples were hospitalized SARI cases that were negative for influenza, SARS-CoV-2 and/or RSV, as applicable to age-based testing algorithms, across 70 laboratories.
resultsOf 8,246 enrolled SARI cases, 4,149 eligible samples were tested for hMPV under the capped weekly sampling strategy, and 59 were positive (1.42%; 95% CI: 1.10-1.83). Positivity ranged from 0.5% to 2.9% across age groups and was highest in children aged <2 years. Most patients (63%) were aged <2 years. Positivity was higher among males (1.7% vs 1.1% in females), and was highest in January (2.1%) before declining to 0.5% in April. The most common symptoms were cough (95%), fever (88%), and breathlessness (58%). Outcomes were available for 54/59 patients: 11 required ICU admission, 51 were discharged alive, and 3 died. Among seven patients with comorbidities, all were discharged alive. More than half of the sequenced viruses belonged to clade B1, followed by B2 and A2b2.
conclusionIn this limited sentinel surveillance of severe respiratory infections, hMPV was detected infrequently but was observed predominantly among young children. Continued multi-season surveillance is needed to better define age-specific burden, temporal patterns, and circulating genotypes in India. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.